Login Join for free
Popular Searches
Popular news More >
SEARCHING....
no results found
  • Real Time Chart Real Time Chart
  • Stock Profile Stock Profile

  • Financials As Reported

    • accession Number 0000950170-23-018811
    • accounts Payable Current 45,153,000
    • accumulated Depreciation Depletion And Amortization Property Plant And Equipment 38,869,000
    • accumulated Other Comprehensive Income Loss Net Of Tax --9,388,000
    • allocated Share Based Compensation Expense 20,875,000
    • amendment Flag false
    • assets 2,244,364,000
    • assets Current 1,907,966,000
    • cash And Cash Equivalents At Carrying Value 344,407,000
    • cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 132,064,000
    • cik 1,674,416
    • city Area Code 41 (0)41
    • common Stock Par Or Stated Value Per Share 0.03
    • common Stock Shares Authorized 150,347,467
    • common Stock Shares Issued 79,044,050
    • common Stock Shares Outstanding 78,863,734
    • comprehensive Income Net Of Tax --46,806,000
    • current Fiscal Year End Date --12-31
    • date Filed 2023-05-08
    • depreciation 5,000,000
    • depreciation Depletion And Amortization 5,051,000
    • document Fiscal Period Focus Q1
    • document Fiscal Year Focus 2,023
    • document Period End Date 2023-03-31
    • document Transition Report false
    • document Type 10-Q
    • earnings Per Share Basic -0.67
    • earnings Per Share Diluted -0.67
    • effective Income Tax Rate Continuing Operations -0.026
    • entity Address Address Line 1 Baarerstrasse 14
    • entity Address City Or Town Zug
    • entity Address Postal Zip Code 6,300
    • entity Central Index Key 1,674,416
    • entity Current Reporting Status Yes
    • entity Emerging Growth Company false
    • entity File Number 001-37923
    • entity Filer Category Large Accelerated Filer
    • entity Incorporation State Country Code V8
    • entity Interactive Data Current Yes
    • entity Name CRISPR Therapeutics AG
    • entity Registrant Name CRISPR THERAPEUTICS AG
    • entity Shell Company false
    • entity Small Business false
    • entity Tax Identification Number 00-0000000
    • income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest --51,745,000
    • income Tax Expense Benefit 1,300,000
    • increase Decrease In Accounts Receivable 0
    • increase Decrease In Contract With Customer Liability 0
    • increase Decrease In Other Operating Liabilities --170,000
    • irs Number 473,173,478
    • liabilities 389,468,000
    • liabilities And Stockholders Equity 2,244,364,000
    • liabilities Current 146,794,000
    • local Phone Number 561 32 77
    • marketable Securities Current 1,538,763,000
    • marketable Securities Noncurrent 6,300,000
    • net Cash Provided By Used In Financing Activities 5,404,000
    • net Cash Provided By Used In Investing Activities 117,829,000
    • net Cash Provided By Used In Operating Activities 8,799,000
    • net Income Loss --53,065,000
    • nonoperating Income Expense 12,742,000
    • operating Expenses 164,487,000
    • operating Income Loss --64,487,000
    • operating Lease Liability Current 15,717,000
    • operating Lease Liability Noncurrent 224,552,000
    • operating Lease Right Of Use Asset 153,346,000
    • other Assets Noncurrent 2,760,000
    • other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax 32,000
    • other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 6,259,000
    • other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 6,227,000
    • other Liabilities Current 20,000
    • other Liabilities Noncurrent 5,799,000
    • other Noncash Income Expense 969,000
    • other Nonoperating Income Expense 12,742,000
    • payments To Acquire Property Plant And Equipment 3,059,000
    • period End 1,680,220,800,000
    • period Start 1,672,531,200,000
    • property Plant And Equipment Gross 201,067,000
    • property Plant And Equipment Net 162,198,000
    • report Link https://www.sec.gov/Archives/edgar/data/1674416/000095017023018811/crsp-20230331_htm.xml
    • research And Development Expense 99,935,000
    • retained Earnings Accumulated Deficit --899,155,000
    • revenue From Contract With Customer Excluding Assessed Tax 100,000,000
    • share Based Compensation 20,875,000
    • stockholders Equity 1,854,896,000
    • trading Symbol CRSP
    • update 1970-01-01
    • weighted Average Number Of Diluted Shares Outstanding 78,676,986
    • weighted Average Number Of Shares Outstanding Basic 78,676,986
    • id REPORTED_FINANCIALS
    • key CRSP
    • subkey 10-Q
    • date 2023-05-08
    • updated 2023-05-09
  • Symbol Info Symbol Info
  • Symbol Over View Symbol Over View
  • Technical Analysis Technical Analysis

CRSP stock fundamentals - financials as reported

Financials As Reported

  • accession Number 0000950170-23-018811
  • accounts Payable Current 45,153,000
  • accumulated Depreciation Depletion And Amortization Property Plant And Equipment 38,869,000
  • accumulated Other Comprehensive Income Loss Net Of Tax --9,388,000
  • allocated Share Based Compensation Expense 20,875,000
  • amendment Flag false
  • assets 2,244,364,000
  • assets Current 1,907,966,000
  • cash And Cash Equivalents At Carrying Value 344,407,000
  • cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 132,064,000
  • cik 1,674,416
  • city Area Code 41 (0)41
  • common Stock Par Or Stated Value Per Share 0.03
  • common Stock Shares Authorized 150,347,467
  • common Stock Shares Issued 79,044,050
  • common Stock Shares Outstanding 78,863,734
  • comprehensive Income Net Of Tax --46,806,000
  • current Fiscal Year End Date --12-31
  • date Filed 2023-05-08
  • depreciation 5,000,000
  • depreciation Depletion And Amortization 5,051,000
  • document Fiscal Period Focus Q1
  • document Fiscal Year Focus 2,023
  • document Period End Date 2023-03-31
  • document Transition Report false
  • document Type 10-Q
  • earnings Per Share Basic -0.67
  • earnings Per Share Diluted -0.67
  • effective Income Tax Rate Continuing Operations -0.026
  • entity Address Address Line 1 Baarerstrasse 14
  • entity Address City Or Town Zug
  • entity Address Postal Zip Code 6,300
  • entity Central Index Key 1,674,416
  • entity Current Reporting Status Yes
  • entity Emerging Growth Company false
  • entity File Number 001-37923
  • entity Filer Category Large Accelerated Filer
  • entity Incorporation State Country Code V8
  • entity Interactive Data Current Yes
  • entity Name CRISPR Therapeutics AG
  • entity Registrant Name CRISPR THERAPEUTICS AG
  • entity Shell Company false
  • entity Small Business false
  • entity Tax Identification Number 00-0000000
  • income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest --51,745,000
  • income Tax Expense Benefit 1,300,000
  • increase Decrease In Accounts Receivable 0
  • increase Decrease In Contract With Customer Liability 0
  • increase Decrease In Other Operating Liabilities --170,000
  • irs Number 473,173,478
  • liabilities 389,468,000
  • liabilities And Stockholders Equity 2,244,364,000
  • liabilities Current 146,794,000
  • local Phone Number 561 32 77
  • marketable Securities Current 1,538,763,000
  • marketable Securities Noncurrent 6,300,000
  • net Cash Provided By Used In Financing Activities 5,404,000
  • net Cash Provided By Used In Investing Activities 117,829,000
  • net Cash Provided By Used In Operating Activities 8,799,000
  • net Income Loss --53,065,000
  • nonoperating Income Expense 12,742,000
  • operating Expenses 164,487,000
  • operating Income Loss --64,487,000
  • operating Lease Liability Current 15,717,000
  • operating Lease Liability Noncurrent 224,552,000
  • operating Lease Right Of Use Asset 153,346,000
  • other Assets Noncurrent 2,760,000
  • other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax 32,000
  • other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 6,259,000
  • other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 6,227,000
  • other Liabilities Current 20,000
  • other Liabilities Noncurrent 5,799,000
  • other Noncash Income Expense 969,000
  • other Nonoperating Income Expense 12,742,000
  • payments To Acquire Property Plant And Equipment 3,059,000
  • period End 1,680,220,800,000
  • period Start 1,672,531,200,000
  • property Plant And Equipment Gross 201,067,000
  • property Plant And Equipment Net 162,198,000
  • report Link https://www.sec.gov/Archives/edgar/data/1674416/000095017023018811/crsp-20230331_htm.xml
  • research And Development Expense 99,935,000
  • retained Earnings Accumulated Deficit --899,155,000
  • revenue From Contract With Customer Excluding Assessed Tax 100,000,000
  • share Based Compensation 20,875,000
  • stockholders Equity 1,854,896,000
  • trading Symbol CRSP
  • update 1970-01-01
  • weighted Average Number Of Diluted Shares Outstanding 78,676,986
  • weighted Average Number Of Shares Outstanding Basic 78,676,986
  • id REPORTED_FINANCIALS
  • key CRSP
  • subkey 10-Q
  • date 2023-05-08
  • updated 2023-05-09

Related News

ARKG ETF Rips 10.32% to a Record $47.67 as the First mRNA Cancer Vaccine Clears Phase 3

ARKG ETF Rips 10.32% to a Record $47.67 as the First mRNA Cancer Vaccine Clears Phase 3

Itai Smidt 21.08.26
Stocks Markets TXG TWST TEM CRSP
Broadcom Climbs to $367 on $100B AI Financing Report as Stock Sits 21% Below Its June Peak

Broadcom Climbs to $367 on $100B AI Financing Report as Stock Sits 21% Below Its June Peak

Itai Smidt 21.08.26
Stocks AVGO MU AMD NVDA
Ross Stores Rips 9.1% to $249.68 as Q2 EPS Hits $2.66, Comps Climb 10%

Ross Stores Rips 9.1% to $249.68 as Q2 EPS Hits $2.66, Comps Climb 10%

Itai Smidt 21.08.26
Stocks ROST TJX BURL WMT
BJ's Wholesale Jumps 4% to $94.90 as Q2 EPS Hits $1.36, Membership Tops 8.5M and FY26 Guidance Goes to $4.80

BJ's Wholesale Jumps 4% to $94.90 as Q2 EPS Hits $1.36, Membership Tops 8.5M and FY26 Guidance Goes to $4.80

Itai Smidt 21.08.26
Stocks BJ COST WMT TGT
Dow Rips 395 Points to 53,154.64, S&P 500 Hits 7,671.51 as Bitcoin Blows Through $79,000

Dow Rips 395 Points to 53,154.64, S&P 500 Hits 7,671.51 as Bitcoin Blows Through $79,000

Itai Smidt 21.08.26
Stocks Markets HOOD MRNA COIN BABA
One Trial Readout Put 12 Points of NAV Into a $171 Million Genomics Fund

One Trial Readout Put 12 Points of NAV Into a $171 Million Genomics Fund

Itai Smidt 20.08.26
Stocks Markets TWST MRNA RVMD GMAB
Trade Now
© Trading News. All Rights Reserved Since 2022